Evidence map›Paper›PMID 38497192›Full record

SynthesisJournal of comparative effectiveness research2024

Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods.

Joseph Biskupiak, Gary Oderda, Diana Brixner, Todd L Wandstrat

Open access · diamondAbstract readComparative StudySystematic Review
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Estimation of EDDrug design, development and therapy · 2025
    Trial
  5. Article
  6. Article
  7. Determination of EDBMC anesthesiology · 2025
    Article
  8. Article
  9. Overview and Prospects of the Clinical Application of Oliceridine.Drug design, development and therapy · 2025
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joseph BiskupiakCollege of Pharmacy, University of Utah, UT USA.
Gary OderdaCollege of Pharmacy, University of Utah, UT USA.
Diana BrixnerCollege of Pharmacy, University of Utah, UT USA.
Todd L WandstratTrevena, Inc., PA USA.ORCID 0000-0003-2291-4893
University of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute PainFentanylHydromorphoneNauseaSpiro CompoundsThiophenesVomitingAdministration, IntravenousAnalgesics, OpioidHumansPain ManagementRandomized Controlled Trials as TopicRespiratory Insufficiency((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineAnalgesics, OpioidFentanylHydromorphoneSpiro CompoundsThiophenesfentanylhydromorphoneindirect treatment comparisonmorphinenausea and vomitingoliceridinepain management

Identifiers

PMID38497192
PMCPMC11036942
OpenAlexW4392925638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.